

# Cancer Drug Discovery

Kyu-Won Kim • Jae Kyung Roh  
Hee-Jun Wee • Chan Kim

# Cancer Drug Discovery

Science and History

 Springer

Kyu-Won Kim  
College of Pharmacy  
Seoul National University  
Seoul  
Korea (Republic of)

Hee-Jun Wee  
College of Pharmacy  
Seoul National University  
Seoul  
Korea (Republic of)

Jae Kyung Roh  
Department of Internal Medicine  
Yonsei University College of Medicine  
Seoul  
Korea (Republic of)

Chan Kim  
Department of Internal Medicine  
CHA Bundang Medical Center  
Seongnam  
Korea (Republic of)

Originally published by PanMun Education Co., Seoul, 2015  
ISBN 978-94-024-0842-3      ISBN 978-94-024-0844-7 (eBook)  
DOI 10.1007/978-94-024-0844-7

Library of Congress Control Number: 2016958571

© Springer Science+Business Media Dordrecht 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

This Springer imprint is published by Springer Nature  
The registered company is Springer Science+Business Media B.V. Dordrecht

# Preface

This book was written with the aim to provide a comprehensive and multifaceted overview of the history of the development of anticancer drugs and to present future directions for the development of new anticancer drugs. First, this book examines the scientific progress in biological science periodically and the influence such progress had in cancer research. Furthermore, this book outlines the development process of anticancer drugs with a focus on the characteristic drug groups of each era, in relation with the advancements in the relevant fields of chemistry and biological science and also presents a brief mechanism of the drugs. After examining the side effects of each anticancer drug and the treatments for alleviating the effects, this book finally sums up the limitations of the current anticancer drugs and seeks new directions for the development of anticancer drugs.

During the last 60 years, research in biological science has centered on the cell, and cellular molecules, with an emphasis on the activities and functions of various genes. Accordingly, cancer research has also focused on cancer cells; the differences between normal cells and cancer cells, including their genetic variations, were discovered and corresponding molecule-targeted anticancer drugs developed.

The development process of anticancer drugs indicates that leukemia, which can be easily observed through the microscope, served as the model during the early days of cancer research and that the rapid proliferation of the leukemia cells was accepted as the general characteristic of cancer cells. As a result, development of anticancer drugs that have anti-proliferative effects began, starting with the alkylating agent in 1946, based on the unity assumption that all cancer cells characteristically grows abnormally. The search for a standard treatment for all cancers was launched through the development of such cytotoxic anticancer drugs.

Alkylating agents, which are one of the first types of anticancer drugs developed during this process, inhibit persistent cell proliferation, which is the representative feature of cancers, by causing DNA damage, and was developed especially during the 1940s to the early 1970s. The second type, antimetabolites, have been developed since the late 1940s and display structural mimicry with precursors of DNA synthesis, thus inhibiting cell proliferation by inhibiting activities of various enzymes contributing to DNA replication. In addition, as a result of a large-scale drug screen-

ing that began in 1954, plant alkaloids and anticancer antibiotics were developed from the 1960s and continued to be developed until the 1990s. Anticancer drug screenings on chemical molecules also proceeded at the same time, leading to the development of various chemical anticancer drugs from the mid-1960s which continued to be developed until the mid-2000s. These drugs form the third type of anticancer drugs. The fourth type of anticancer drugs, consisting of immunotherapy and miscellaneous anticancer drugs, were developed in the mid-1960s, proceeded to be developed from the 1980s to the 1990s and are still consistently being developed. Immunotherapy anticancer drugs, which activate the immune system to eliminate cancer cells, include cytokines such as interferons, humanized antibodies, and dendritic cells, while asparaginase and others were developed as miscellaneous type of anticancer drugs. Before the molecule-targeted anticancer drugs were developed, the fifth type of anticancer drugs, hormonal cancer drugs were developed for treating several cancers based on the understanding of the biological characteristics of cancers. Hormonal anticancer drugs for treating testosterone- or estrogen-dependent cancers such as diethylstilbestrol or tamoxifen were developed from the 1940s and are continued to be used today. Beginning from the 1990s, new types of molecule-targeted anticancer drugs were rapidly developed, forming the sixth type of anticancer drugs. Molecule-targeted anticancer drugs are products of in-depth biological research on cancers that was intensified from the 1980s. In other words, molecular mechanisms of tumorigenesis and malignancy were better understood by extensive research which used molecular biology as its major research technologies. In particular, various factors that play important roles in various types of cancers were discovered, facilitating the development of new drugs targeting the discovered factors. These molecule-targeted anticancer drugs are forming a major anticancer drug group starting from the 2000s.

Accordingly, this book presents an overview of the scientific discoveries and history of the development of anticancer drugs in the following order. Chapter 1 summarizes the characteristics of cancer in accordance to the development of science. This chapter describes the characteristics of the cancer cells based on the research that focused exclusively on cancer cells, similarly to biological science which mainly focuses on cells. Moreover, this chapter provided characteristics of cancer which interacts with its surrounding microenvironment. In particular, this chapter provides a systematic explanation of cancer in relation with the vascular system, lymphatic system, and immune system, which also relates to the new research prospects presented in the final chapter of this book. Chapter 2 examined the relation between the development of biological science since the advent of the cell theory in 1838 with the corresponding history of cancer research and development of anticancer drugs and summarized the relation through a chronological table. Chapter 3 provided images that explain a historical background of cancer chemotherapy and describe chronologically the developmental history of screening systems of anticancer drugs. Chapters 4–9 classified the characteristics and effects of approximately 160 anticancer drugs, which used the screening system described in Chapter 3 for development, into 6 groups and provided a comprehensive account of the development process and history of each group. Chapter 10 provided details on the side

effects of the clinical use of the anticancer drugs introduced in Chapters 4–9, along with the drugs that can alleviate such side effects. Finally, in Chapter 11, this book provided new anticancer drugs that will be researched and developed, based on research focusing on the difference between cancer cells and normal cells which has been conducted since the 1980s. This book also suggested a cell network research for a next research methodology, based on the perspective that cancer is related with various systemic characteristics of the human body. In other words, this book emphasizes that the research on cell network of the tissue level is necessary.

This book, in short, is a review of the past and current research conducted on anticancer drugs and a proposal for a new direction of cancer research for the future. I would like to express my gratitude to Professor Jae Kyung Roh, Dr. Hee-Jun Wee, and Dr. Chan Kim for joining me as co-authors to write this book. I also thank my graduate students at the research center who helped me with the images and tables included in this book. I also extend my gratitude to Professor Seishi Murakami at the Cancer Research Institute of Kanazawa University, Japan, who has always been a source of advice and encouragement throughout the past 35 years of research on cancer. Lastly, I thank Dr. Jeong Hun Kim at Seoul National University Hospital who helped me throughout my personal ailment. This book would not have been published without their help.

Seoul, Korea  
January, 2016

Kyu-Won Kim

# Contents

## Part I A Scientific Overview on Cancer

<b>1 Advancements in Life Sciences and Characteristic Features of Cancer Cells.</b> . . . . .	3
1.1 Characteristics of Cancer Cells . . . . .	5
1.2 Characteristic Interactions of Cancer Cells with Neighboring Cells and the Tumor Microenvironment. . . . .	9
1.2.1 Stromal Cells . . . . .	9
1.2.2 Angiogenesis . . . . .	16
1.2.3 Metastasis of Malignant Cancer. . . . .	19
1.2.4 Avoidance of Immune Surveillance. . . . .	21
1.2.5 Tumor-Promoting Inflammatory Responses . . . . .	22
References. . . . .	23
<b>2 Advancement of the Science and History of Cancer and Anticancer Drugs.</b> . . . . .	25
References. . . . .	54

## Part II Cancer Drug Discovery: Types and History

<b>3 Chronology of Anticancer Drug Development.</b> . . . . .	59
3.1 A Historical Background of Cancer Chemotherapy . . . . .	59
3.2 Development of the Anticancer Drug Screening Systems . . . . .	60
3.2.1 Transplantable Tumor Models in Animals. . . . .	60
3.2.2 Chemical Tumor Induction and Anticancer Drug Screening Using Inbred Mice. . . . .	61
3.2.3 Solid Tumor Animal Models and Xenograft Screening Methods. . . . .	62
3.2.4 Anticancer Drug Screening Methods Based on Human Cancer Cell Lines. . . . .	63
3.2.5 Mechanism-Based Anticancer Agent Screening Method . . . . .	63

3.3	Chronology of the Anticancer Drug Development	64
3.4	Clinical Application of Anticancer Drugs	68
	References	69
<b>4</b>	<b>Alkylating Anticancer Drugs</b>	<b>71</b>
4.1	Classical Alkylating Drugs	73
4.1.1	Bis Amine/Nitrogen Mustards	73
4.1.2	Alkyl Sulfonate: Busulfan	80
4.1.3	Aziridines (Ethylenimines)	81
4.1.4	Nitrosoureas	83
4.2	Nonclassical Alkylating Drugs	85
4.2.1	Hydrazine: Procarbazine	85
4.2.2	Triazenes	86
4.2.3	Altretamines	88
4.3	Alkylating-Like Agents: Platinum Compounds	88
4.3.1	Cisplatin	89
4.3.2	Carboplatin	90
4.3.3	Oxaliplatin	91
	References	91
<b>5</b>	<b>Antimetabolic Anticancer Drugs</b>	<b>95</b>
5.1	Folic Acid Derivatives	95
5.1.1	Methotrexate	96
5.1.2	Pemetrexed	98
5.1.3	Pralatrexate	99
5.2	Purine Analogs	100
5.2.1	6-Mercaptopurine and 6-Thioguanine	100
5.2.2	Fludarabine	101
5.2.3	Pentostatin (2'-deoxycoformycin)	102
5.2.4	Cladribine	103
5.2.5	Clofarabine	104
5.2.6	Nelarabine	104
5.3	Pyrimidine Analogs	105
5.3.1	Fluoropyrimidines	105
5.3.2	Deoxycytidine	108
	References	110
<b>6</b>	<b>Natural Product Anticancer Drugs</b>	<b>113</b>
6.1	Plant-Derived Anticancer Drugs	114
6.1.1	Vinca Alkaloids	114
6.1.2	Macrolide: Eribulin	116
6.1.3	Taxane	117
6.1.4	Ixabepilone	120
6.1.5	Podophyllotoxins: Topoisomerase II Inhibitors	120
6.1.6	Camptothecins: Topoisomerase I Inhibitors	122
6.1.7	Omacetaxine Mepesuccinate (Homoharringtonine, HHT)	123



6.2	Anticancer Antibiotics . . . . .	125
6.2.1	Actinomycin D (Dactinomycin) . . . . .	126
6.2.2	Anthracycline . . . . .	126
6.2.3	Mithramycin (Plicamycin) . . . . .	130
6.2.4	Bleomycin . . . . .	130
	References . . . . .	131
<b>7</b>	<b>Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs . . . . .</b>	<b>135</b>
7.1	Immunotherapeutic Anticancer Drugs . . . . .	135
7.1.1	Cytokines . . . . .	136
7.1.2	Denileukin Diftitox (DAB389IL2) . . . . .	138
7.1.3	Levamisole . . . . .	139
7.1.4	BCG (Bacillus Calmette-Guérin) . . . . .	140
7.1.5	Imiquimod . . . . .	141
7.1.6	Ipilimumab . . . . .	142
7.1.7	Sipuleucel-T . . . . .	143
7.1.8	Thalidomide . . . . .	144
7.1.9	Lenalidomide and Pomalidomide . . . . .	145
7.2	Other Miscellaneous Anticancer Drugs . . . . .	146
7.2.1	Mitotane (o,p-Dichlorodiphenyldichloroethane) . . . . .	146
7.2.2	Asparaginase . . . . .	146
7.2.3	Porfimer Sodium: Photodynamic Therapy (PDT) . . . . .	147
7.2.4	Arsenic Trioxide . . . . .	148
7.2.5	Hydroxyurea (Hydroxycarbamide) . . . . .	149
	References . . . . .	150
<b>8</b>	<b>Hormonal Anticancer Drugs . . . . .</b>	<b>155</b>
8.1	Hormonal Anti-prostate-Cancer Drugs . . . . .	155
8.1.1	LHRH Agonists/Antagonists . . . . .	158
8.1.2	Anti-androgens . . . . .	159
8.1.3	CYP17A1 Inhibitor: Abiraterone . . . . .	161
8.2	Hormonal Anti-breast-Cancer Drugs . . . . .	162
8.2.1	Selective Estrogen Receptor Modulator (SERM) . . . . .	163
8.2.2	Anti-estrogen: Fulvestrant . . . . .	165
8.2.3	Aromatase (CYP29) Inhibitors . . . . .	167
8.3	Other Hormonal Anticancer Drugs . . . . .	169
8.3.1	Prednisone . . . . .	169
8.3.2	Testolactone . . . . .	169
8.3.3	Progestin . . . . .	170
8.3.4	Somatostatin . . . . .	170
	References . . . . .	171
<b>9</b>	<b>Molecular Targeted Anticancer Drugs . . . . .</b>	<b>175</b>
9.1	Tretinoin (All- <i>Trans</i> Retinoic Acid, ATRA) . . . . .	179
9.2	Bcr-Abl Inhibitors . . . . .	180
9.2.1	First Generation Bcr-Abl Inhibitor: Imatinib . . . . .	181
9.2.2	Second Generation Bcr-Abl Inhibitors . . . . .	184

9.3	EGFR Inhibitors . . . . .	186
9.3.1	First Generation EGFR Inhibitors . . . . .	187
9.3.2	Afatinib: Second Generation EGFR Inhibitor . . . . .	189
9.3.3	Monoclonal Antibodies Against EGFR . . . . .	190
9.4	HER2 Inhibitors . . . . .	192
9.4.1	Monoclonal Antibodies Against HER2 . . . . .	193
9.4.2	HER2 Small Molecule Inhibitors. . . . .	195
9.5	Angiogenesis Inhibitors . . . . .	196
9.5.1	Bevacizumab . . . . .	196
9.5.2	Aflibercept . . . . .	198
9.5.3	Small Molecule VEGFR Inhibitors: Multi-targeted Kinase Inhibitors . . . . .	198
9.6	Other Kinase Inhibitors . . . . .	204
9.6.1	Ruxolitinib: JAK-1,2 Inhibitor. . . . .	204
9.6.2	Crizotinib: ALK and ROS1 Inhibitor. . . . .	206
9.6.3	B-Raf Kinase Inhibitors . . . . .	207
9.6.4	Trametinib: MEK Inhibitor . . . . .	208
9.6.5	Ibrutinib . . . . .	209
9.7	mTOR Inhibitors . . . . .	210
9.7.1	Temsirolimus . . . . .	211
9.7.2	Everolimus . . . . .	211
9.8	Other Targeted Anticancer Antibody Drugs. . . . .	212
9.8.1	Rituximab. . . . .	212
9.8.2	Ibritumomab Tiuxetan . . . . .	214
9.8.3	Tositumomab Iodine-131 . . . . .	214
9.8.4	Alemtuzumab. . . . .	215
9.8.5	Ofatumumab . . . . .	215
9.8.6	Brentuximab Vedotin . . . . .	215
9.8.7	Obinutuzumab . . . . .	217
9.9	Epigenetic Anticancer Drugs . . . . .	217
9.9.1	DNA Methylation Inhibitors: Azanucleosides. . . . .	217
9.9.2	Histone Deacetylase (HDAC) Inhibitors . . . . .	219
9.10	Proteasome Inhibitors . . . . .	222
9.10.1	Bortezomib. . . . .	222
9.10.2	Carfilzomib . . . . .	224
9.11	Vismodegib: Hedgehog Pathway Blocker . . . . .	224
	References. . . . .	226
<b>10</b>	<b>Complications of Anticancer Drugs and Their Management. . . . .</b>	<b>239</b>
10.1	Chemotherapy-Induced Nausea and Vomiting (CINV) . . . . .	239
10.1.1	Emetogenic Risk of Anticancer Drugs. . . . .	240
10.1.2	Types of Anti-emetics . . . . .	240
10.1.3	Prevention and Treatment of Chemotherapy- Induced Nausea and Vomiting . . . . .	242
10.2	Myelotoxicity (Bone Marrow Toxicity). . . . .	243
10.2.1	Neutropenia . . . . .	243
10.2.2	Anemia. . . . .	243

10.2.3	Thrombocytopenia . . . . .	244
10.3	Chemotherapy-Induced Diarrhea . . . . .	245
10.3.1	Cause of Diarrhea . . . . .	245
10.3.2	Treatment . . . . .	245
10.4	Chemotherapy-Induced Constipation . . . . .	245
10.4.1	Cause of Constipation . . . . .	245
10.4.2	Treatment . . . . .	246
10.5	Chemotherapy-Induced Urinary Toxicity . . . . .	246
10.5.1	Cisplatin-Induced Nephrotoxicity . . . . .	246
10.5.2	Hemorrhagic Cystitis . . . . .	246
10.5.3	Nephrotoxicity of Targeted Agents . . . . .	247
10.6	Chemotherapy-Induced Pulmonary Toxicity . . . . .	247
10.6.1	Bleomycin-Induced Pulmonary Fibrosis . . . . .	247
10.7	Chemotherapy-Induced Neurotoxicity . . . . .	248
10.7.1	Platinum-Induced Neurotoxicity . . . . .	248
10.7.2	Methotrexate-Induced Neurotoxicity . . . . .	248
10.7.3	Taxane-Induced Neurotoxicity . . . . .	248
10.8	Cardiotoxicity . . . . .	249
10.8.1	Chemotherapy-Induced Cardiotoxicity . . . . .	249
10.8.2	Anthracycline-Induced Cardiotoxicity . . . . .	249
10.9	Chemotherapy-Induced Oral Mucositis . . . . .	250
10.9.1	Pathogenesis and Clinical Features . . . . .	250
10.9.2	Prevention and Treatment . . . . .	250
10.10	Anorexia . . . . .	251
10.11	Tumor Lysis Syndrome . . . . .	251
10.12	Extravasation of Anticancer Drugs . . . . .	253
10.12.1	Skin Irritation from Extravasation of Anticancer Drugs . . . . .	253
10.12.2	Treatment of Extravasation . . . . .	253
10.13	Chemotherapy-Induced Skin Toxicity . . . . .	254
10.13.1	Hyperpigmentation . . . . .	254
10.13.2	Nail Change . . . . .	255
10.13.3	Hand-Foot Syndrome (Palmar-Plantar Erythrodysesthesia) . . . . .	255
10.13.4	Acneiform Eruption . . . . .	255
	References . . . . .	255

### Part III A Paradigm Shift in Cancer Research

<b>11</b>	<b>Advancements in Bioscience and New Cancer Drugs . . . . .</b>	<b>259</b>
11.1	Development of Cancer Drugs According to Scientific Advancements . . . . .	259
11.2	New Anticancer Drugs . . . . .	261
11.2.1	Development of Novel Targeted Agents . . . . .	261
11.2.2	Future Research Prospects According to the Paradigm Shift . . . . .	264
	References . . . . .	276

# Contributors

## **Kyu-Won Kim**

1976                      College of Pharmacy, Seoul National University, Seoul,  
Korea  
B.S.

1985                      University of Minnesota, Minneapolis, U.S.A.  
Ph.D.

### Professional Training:

2000–Present            Professor  
College of Pharmacy, Seoul National University, Korea

2001–Present            Full member  
The Korean Academy of Science and Technology

2011–2012              Vice-chairman  
The Korean Cancer Association

1987–2000              Assistant Professor, Associate Professor, Professor  
Department of Molecular Biology  
Pusan National University, Korea

1985–1987              Postdoctoral Fellow  
Department of Cancer Genetics  
  
Dana-Farber Cancer Institute, Harvard Medical School,  
USA

## Awards and Honors:

- 2005 Ho-Am Prize in medicine, Ho-Am Foundation
- 2003 The Highest Award for Korea Science, the President of Korea

**Jae Kyung Roh**

- 1973 Yonsei University, College of Medicine, Seoul, Korea  
M.D.
- 1990 Yonsei University, Graduate School, Seoul, Korea  
Ph.D.

## Professional Training:

- 2014–Present Professor Emeritus  
Yonsei Cancer Center, Yonsei University College of Medicine  
Honorary Director  
Cheil Hospital Women’s Cancer Center, Seoul, Korea
- 1981–2014 Assistant Professor, Professor in Medicine  
Division of Medical Oncology, Yonsei Cancer Center
- 2008–2011 Chairman  
National Bioethics Committee, Korea
- 2006–2008 Chairman  
Board of Directors, The Korean Cancer Association
- 2005–2011 Vice President(Health Division)  
The Korean Federation of Science & Technology Societies(KOFST)
- 2000–2010 Director  
Cancer Metastasis Research Center, Yonsei University College of Medicine
- 1983–1986 Fellow in Medical Oncology  
Vincent T. Lombardi Cancer Research Center,  
Georgetown University, School of Medicine, Washington,  
D.C., USA

## Awards and Honors:

- 2014 ROK Order of Service Merit (4th Class) Green Stripes

**Hee-Jun Wee**

1989 Pusan National University, Pusan, Korea  
B.S.

2003 Kyoto University, Kyoto, Japan  
Ph.D.

## Professional Training:

2010–Present Research Assistant Professor  
College of Pharmacy, Seoul National University, Korea

2006–2010 Research Assistant Professor  
Department of Biochemistry, School of Medicine,  
Chungbuk National University, South Korea

2003–2006 Research Fellow  
Institute of Molecular and Cell Biology, Singapore

**Chan Kim**

2005 Yonsei University College of Medicine, Seoul, Korea  
M.D.

2013 Korea Advanced Institute of Science and Technology  
(KAIST), Daejeon, Korea  
Ph.D.

## Professional Training:

2015–Present Assistant Professor  
Medical Oncology, CHA Bundang Medical Center, CHA  
University, Seongnam, Korea

2014–2015 Clinical Fellow  
Yonsei Cancer Center, Severance Hospital, Seoul, Korea

2013–2014 Postdoctoral Fellow  
Laboratory of Vascular Biology and Stem Cells, KAIST,  
Daejeon, Korea

2006–2010 Residency in Internal Medicine  
Severance Hospital, Seoul, Korea

2005–2006 Rotating Internship  
Severance Hospital, Seoul, Korea